PSA Recurrence Overdetected After Prostatectomy

Share this content:
For some men, prostate cancer recurrence may be overdetected, especially in those over 70.
For some men, prostate cancer recurrence may be overdetected, especially in those over 70.

Prostate-specific antigen recurrence (PSA-R) may be overdetected after radical prostatectomy (RP), according to research published in Clinical Cancer Research.

Jing Xia, Ph.D., from the Fred Hutchinson Cancer Research Center in Seattle, and colleagues estimated the times from PSA-R to metastasis for 441 patients with RP who did not receive salvage treatment at PSA-R. Using U.S. life tables to reflect other-cause survival among RP cases in the Surveillance, Epidemiology, and End Results (SEER) registry, the authors examined the times to other-cause death.

The chance that other-cause death would precede clinical metastasis was estimated for 4,455 patients with disease characteristics based on the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) database.

The researchers found that at five and 10 years, the cumulative incidence of PSA-R was 13.6 and 19.9 percent, respectively, in CaPSURE. In patients with RP in SEER, the risk of other-cause death was 60 percent lower than the age-matched U.S. population.

RELATED: PSA Screening Associated with Reduction in Prostate Cancer Death

Overdetection occurred in at least 9.1 and 15.6 percent of patients with PSA-R less than five years and five to 10 years after RP, respectively. Among patients aged over 70 years at diagnosis who recurred within 10 years of diagnosis, at least 34.1 percent were overdetected.

"The potential for overdetection of recurrence confirms the need for approaches to determine whether and when to initiate salvage therapies," the authors write.

One author disclosed financial ties to Myriad Genetics and providing expert testimony for a medical company.

Reference

  1. Xia, Jing, et al. "Overdetection of Recurrence after Radical Prostatectomy: Estimates Based on Patient and Tumor Characteristics." Clinical Cancer Research. doi: 10.1158/1078-0432.CCR-13-3366. October 15, 2014.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs